PreventiveMD

PreventiveMD is a direct-to-consumer telehealth company selling compounded GLP-1 medications and a catalog of compounded wellness peptides on a cash-pay subscription model. It was founded by Brian Conyer and publishes two named medical advisors: Ashley Froese, DO, board-certified in family medicine, and Barry Breaux, MD.

The model is deliberately minimal. You complete an intake questionnaire, a US-licensed provider reviews it asynchronously — the company says within 24 hours — and if approved, medication ships from a compounding pharmacy. There is no required video visit, no lab work, and no scheduled follow-up program. Ongoing monitoring and dose adjustments are described as included, handled through the platform.

Two things distinguish it from the rest of this comparison set. The first is price: $83/month for compounded semaglutide and $97/month for compounded tirzepatide are the lowest advertised figures we have found from a LegitScript-certified provider. The second is the product catalog, which extends well beyond obesity medicine into NAD+, sermorelin, GHK-Cu, and glutathione — compounded substances marketed for anti-aging, recovery, and general wellness rather than weight management.

<!-- source: https://www.preventivemd.com/ --> <!-- source: https://www.preventivemd.com/protocols/semaglutide -->

This is the most consequential thing to understand before ordering from PreventiveMD, and it applies to every compounded GLP-1 seller, not just this one.

Compounded semaglutide and tirzepatide are not FDA-approved. The FDA has not evaluated them for safety, efficacy, potency, sterility, or manufacturing consistency. PreventiveMD discloses this on its own site.

The regulatory picture as of August 2026:

• The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025.
• Enforcement grace periods ended in April and May 2025. After that, large-scale compounding of these molecules from bulk substances stopped being lawful for 503A and 503B facilities.
• On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, having found no clinical need. The comment period closed at the end of July 2026 and no final rule had issued as of this review.

Sellers still offering compounded GLP-1s generally rely on a narrow provision in FDCA § 503A: a compounded drug that would otherwise be "essentially a copy" of an approved drug is permitted when the prescriber determines that a change produces a significant clinical difference for an identified individual patient. In practice that means custom strengths, added ingredients, or alternative routes.

The unresolved question — and it is genuinely unresolved, not settled against the industry — is whether that patient-specific exception can lawfully support a mass-market telehealth funnel. The FDA's position is that scale is inconsistent with a patient-specific provision. In March 2026 the agency issued 30 warning letters to telehealth companies over compounded GLP-1 marketing, targeting claims of equivalence with approved drugs and private-label branding that obscures who compounded the product. Eli Lilly and Novo Nordisk have both sued compounders and telehealth sellers, and in April 2026 a federal judge allowed Lilly's Lanham Act claims against one telehealth company to proceed past a motion to dismiss.

What this means for you as a buyer: you are not doing anything illegal by purchasing. The regulatory exposure sits with the seller and the pharmacy. The practical risks you carry are product quality you cannot verify, and the possibility that your supply is interrupted if enforcement or a final rule reaches your provider. If you are on a compounded product, it is worth knowing what your transition path to an FDA-approved alternative looks like before you need it.

<!-- source: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list --> <!-- source: https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s --> <!-- source: https://www.pharmtech.com/view/why-the-fda-issued-30-warning-letters-to-telehealth-sites-marketing-compounded-glp-1s -->

Alongside its GLP-1 protocols, PreventiveMD sells compounded NAD+, sermorelin, GHK-Cu, and glutathione at roughly $89–$119 per month.

None of these is an FDA-approved drug for the purposes they are commonly marketed for. Sermorelin is a growth-hormone-releasing analog; NAD+ and glutathione are marketed for energy, longevity, and recovery; GHK-Cu is a copper peptide marketed for skin and tissue repair. The evidence base for the consumer claims attached to these compounds is thin, and the FDA has restricted several peptides from compounding.

We flag this not because it makes the GLP-1 product worse in itself, but because it tells you what kind of company you are buying from. Programs built around obesity medicine — Form Health, for instance, which refuses to prescribe compounded GLP-1s at all on clinical grounds — do not sell longevity peptides. A catalog that treats semaglutide as one SKU among several wellness compounds reflects a different set of clinical priorities, and it is a reasonable thing to weigh.

PreventiveMD runs two distinct pricing tracks.

Compounded track — medication included, no separate membership:

• Compounded semaglutide: from $83/month
• Compounded tirzepatide: from $97/month

Branded track — $49/month membership plus medication:

• Wegovy: membership + from $149/month
• Foundayo (orforglipron, the FDA-approved oral GLP-1): membership + from $149/month
• Zepbound: membership + from $299/month

Treat every one of these as an "as low as" figure tied to the lowest dose in a titration schedule. Standard semaglutide titration runs 0.25 mg up to 2.4 mg over roughly 16 weeks, and cost typically rises with dose. Budget for the higher tiers, not the headline.

The comparison that matters: the branded track here is priced close to what you would pay going direct to the manufacturer through LillyDirect or NovoCare, or through Ro or Hims. Once you account for that, the $83 compounded entry price is the only genuine price advantage PreventiveMD offers — and it is the product with the regulatory and quality questions attached. If you have commercial insurance that covers a branded GLP-1, a program that does prior-authorization work, such as Mochi Health or PlushCare, will almost certainly cost you less than paying cash here.

<!-- source: https://www.preventivemd.com/ -->

PreventiveMD does not require labs to start, and does not require a video visit. A provider reviews your intake questionnaire and prescribes.

For a healthy adult with a straightforward BMI-qualifying profile and an existing primary care relationship, that is a defensible trade — you are getting medication access, not primary care, and you have a doctor elsewhere.

For anyone else it is a real gap. A baseline panel before starting a GLP-1 typically covers A1c or fasting glucose, a lipid panel, kidney and liver function, and thyroid screening. GLP-1s carry a boxed warning for thyroid C-cell tumors, are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, and require care in patients with a history of pancreatitis. A questionnaire relies on you to know and accurately report all of this.

There is also no nutritional support. Muscle-mass loss during rapid GLP-1-driven weight loss is a live clinical concern, and protein and resistance-training guidance meaningfully affects outcomes. Programs like Form Health and WeightWatchers Clinic build that in. PreventiveMD does not.

If you use this program, get baseline labs through your own provider first. That is the single highest-value thing you can do to make a minimal-support program safer.

This is general education, not medical advice. Talk to a licensed prescriber about whether a GLP-1 is appropriate for you.

PreventiveMD holds a 4.8 out of 5 on Trustpilot across 72 reviews as of August 2026, with the large majority at five stars. The recurring themes are fast delivery, medication arriving properly chilled and well packaged, smooth onboarding, and unusually responsive support — several reviewers describe the founder personally resolving their issue.

We take that seriously, and it is why PreventiveMD earns 4.5 out of 5 on user experience — the highest score in that category of any program we cover. Fulfillment and support are the things a cash-pay telehealth service most often gets wrong, and the reported track record here is good.

Three caveats on how much weight to give it:

• The sample is small and young. 72 reviews, on a profile the company claimed in June 2026 and maintains on a paid Trustpilot subscription, with review invitations sent to customers. Trustpilot states plainly that it does not fact-check reviews. None of that means the reviews are fake — solicited reviews are standard practice — but a solicited 72-review base is a weaker signal than an organic one several times its size.
• The company-run subreddit is a support channel, not independent evidence. r/PreventiveMD was created in July 2026 and is operated by the company. There is real user discussion there and the company answers criticism publicly, which is a good sign. It is still company-moderated, so treat it as you would any official forum.
• Customer reviews cannot see the risks that drive this rating down. Reviewers are reporting on delivery and service. Nobody reviewing a telehealth company can tell you whether its core product survives the FDA's pending 503B rule, whether skipping baseline labs was safe for them, or what the peptide catalog implies about clinical priorities. A company can be excellent at logistics and still be selling a product with unresolved regulatory footing. Both things are true here.

<!-- source: https://www.trustpilot.com/review/preventivemd.com --> <!-- source: https://www.reddit.com/r/PreventiveMD/ -->

PreventiveMD makes sense if you are uninsured or your plan flatly excludes weight-loss medication, you are paying cash regardless, you have an existing primary care relationship and can get your own baseline labs, you have read the compounding section above and accept the tradeoff, and price is your binding constraint.

Look elsewhere if you have commercial insurance worth activating — a program that does prior-authorization work will beat cash pricing. If you have Medicare or Medicaid, PreventiveMD cannot help you at all; it bills no insurance of any kind. If you have meaningful clinical complexity — type 2 diabetes, cardiovascular disease, PCOS, a history of pancreatitis, or a thyroid history — a physician-led program with real intake is worth the higher price. If you want to stay on FDA-approved medication only, Form Health and PlushCare prescribe brands exclusively. And if you live in one of the 15 states or DC where PreventiveMD does not operate, the decision is made for you.

PreventiveMD delivers exactly what it advertises: the cheapest compounded GLP-1 access in this comparison set, from a LegitScript-certified provider with named medical advisors, at the cost of essentially all clinical infrastructure.

We rate it 2.9 out of 5 on our published rubric — sixth of the eleven programs we cover, and the highest-scoring of the low-cost cash-pay compounded programs. The price is real and the transparency is better than much of the low-cost compounded market. Customer reception is genuinely strong and the operational transparency is better than most of this market. But the rating reflects three things we cannot look past: a core product that is not FDA-approved and whose legal footing is unresolved, a clinical model with no labs and no required visit, and a catalog that sells longevity peptides next to obesity medication.

If you are paying cash and price is the binding constraint, it is a rational choice — provided you get your own baseline labs and understand what compounded means. For most other readers, the branded cash prices now available through manufacturer-direct channels have narrowed the gap enough that the compounded discount is no longer worth what you give up for it.